Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study

Abstract

Aim: While cardiometabolic disorders and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist, the genetic connections and causes are not clearly understood. This study aimed to explore their shared genetic architecture to elucidate the mechanisms driving their comorbidity.

Methods: Using summary statistics from genome-wide association studies (GWASs) on MASLD and 29 cardiometabolic traits (CMTs), we assessed their genetic correlation and causality, and identified shared genetic loci, genes, pathways, cell types, and tissues. Additionally, shared biological mechanisms were uncovered using single-cell RNA sequencing data.

Results: Significant genetic correlations were detected between MASLD and 17 CMTs, encompassing cardiometabolic diseases, glucose, lipids, adiposity, and inflammatory markers, after adjusting for multiple testing (p.adjust < 0.05). Cross-trait analysis yielded a total of 166 shared risk SNPs (including those located in or near TRIB1, LPL, PNPLA3, GCKR, and PPARG). Subsequent colocalization highlighted 73 genetic loci associated with both MASLD and CMTs, with rs429358 (APOE) consistently prioritized in HyPrColoc. Common genes were identified (such as NPC1, MST1R, TMBIM1, IRAK1BP1, L3MBTL3, RBM6, and RGS19), with significant enrichment in cholesterol metabolism, glucose metabolism, immune inflammation, and long-term depression. Shared tissue-specific heritability enrichment was identified in the liver, adipose, artery, adrenal gland, and brain tissue. Moreover, shared enrichment was observed in specific cell types (epicardial adipocytes, erythroid progenitor cells, hepatocytes, glial cells, macrophages, monocytes, and myeloid cells). The expressions of APOE and LPL, which showed colocalization between MASLD and CMTs, were significantly altered in the macrophages of patients with MASLD compared to those of controls. Causality and potential medications were also explored.

Conclusion: Multiple biological pathways contribute to the comorbidity between MASLD and cardiometabolic disorders, with lipid metabolism emerging as a critical factor. This study provides valuable insight into the possible mechanisms underlying their comorbidity and offers potential directions for future therapeutic innovations.

Keywords

Metabolic dysfunction-associated steatotic liver disease / cardiometabolic disease / cholesterol metabolism / macrophage / nonalcoholic fatty liver disease / obesity / shared genetic architecture / single-cell RNA sequencing

References

[1] Haas JT,Staels B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease.Annu Rev Physiol2016;78:181-205

[2] Lonardo A,Caldwell SH,Targher G.Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:1388-9

[3] Shang Y,Widman L.Risk of cardiovascular disease and loss in life expectancy in NAFLD.Hepatology2022;76:1495-505 PMCID:PMC9790251

[4] Foley CN,Breen PG.A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits.Nat Commun2021;12:764 PMCID:PMC7858636

[5] Li P,Cheng S.Heart-liver axis implications of the new steatotic liver disease nomenclature.Lancet Gastroenterol Hepatol2023;8:1071-2

[6] Baskin KK,Olson EN.The heart-liver metabolic axis: defective communication exacerbates disease.EMBO Mol Med2014;6:436-8 PMCID:PMC3992070

[7] Zhou J,Zhang XJ,Cai J.Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications.Hepatology2021;74:2839-47

[8] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[9] Simon TG,Hagström H,Ludvigsson JF.Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.Gut2022;71:1867-75

[10] Younossi ZM,Stepanova M,Alqahtani S.Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.J Hepatol2024;80:694-701

[11] Oh JH.Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): insights into regional and ethnic differences.Clin Mol Hepatol2024;30:168-70 PMCID:PMC11016475

[12] Rinella ME,Siddiqui MS.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;77:1797-835 PMCID:PMC10735173

[13] Abdelhameed F,Lagojda L.Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD.Curr Obes Rep2024;13:510-31 PMCID:PMC11306269

[14] Isaak A,Jansen C.Myocardial fibrosis and inflammation in liver cirrhosis: MRI study of the liver-heart axis.Radiology2020;297:51-61

[15] Burelle C,Deschênes S.A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis.Commun Biol2024;7:356 PMCID:PMC10959946

[16] Anstee QM, Darlay R, Cockell S, et al; EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort^☆. J Hepatol. 2020;73:505-15.

[17] Claussnitzer M,Collins R.A brief history of human disease genetics.Nature2020;577:179-89 PMCID:PMC7405896

[18] Sonehara K.Leveraging genome-wide association studies to better understand the etiology of cancers.Cancer Sci2025;116:288-96 PMCID:PMC11786324

[19] Lau PP,Lin MR,Wan YY.Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities.Cell Biosci2025;15:19 PMCID:PMC11807309

[20] Torgersen K,Bahrami S.Shared genetic loci between depression and cardiometabolic traits.PLoS Genet2022;18:e1010161 PMCID:PMC9170110

[21] Trépo E.Update on NAFLD genetics: from new variants to the clinic.J Hepatol2020;72:1196-209

[22] Eslam M.Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.Nat Rev Gastroenterol Hepatol2020;17:40-52

[23] Hong X,Cao W.Cardiometabolic traits in adult twins: heritability and BMI impact with age.Nutrients2022;15:164 PMCID:PMC9824881

[24] Ghodsian N,Emdin CA.Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease.Cell Rep Med2021;2:100437 PMCID:PMC8606899

[25] Bulik-Sullivan B, Finucane HK, Anttila V, et al; ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236-41.

[26] Burgess S,Thompson SG.Mendelian randomization analysis with multiple genetic variants using summarized data.Genet Epidemiol2013;37:658-65 PMCID:PMC4377079

[27] Burgess S.Interpreting findings from Mendelian randomization using the MR-Egger method.Eur J Epidemiol2017;32:377-89 PMCID:PMC5506233

[28] Bowden J,Haycock PC.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator.Genet Epidemiol2016;40:304-14 PMCID:PMC4849733

[29] Hu X,Lin Z.Mendelian randomization for causal inference accounting for pleiotropy and sample structure using genome-wide summary statistics.Proc Natl Acad Sci U S A2022;119:e2106858119 PMCID:PMC9282238

[30] Purcell S,Todd-Brown K.PLINK: a tool set for whole-genome association and population-based linkage analyses.Am J Hum Genet2007;81:559-75 PMCID:PMC1950838

[31] Hemani G,Elsworth B.The MR-Base platform supports systematic causal inference across the human phenome.Elife2018;7:e34408 PMCID:PMC5976434

[32] O’Connor LJ.Distinguishing genetic correlation from causation across 52 diseases and complex traits.Nat Genet2018;50:1728-34 PMCID:PMC6684375

[33] Turley P, Walters RK, Maghzian O, et al; 23andMe Research Team, Social Science Genetic Association Consortium. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet. 2018;50:229-37. PMCID:PMC5805593

[34] Zhu X, Feng T, Tayo BO, et al; COGENT BP Consortium. Meta-analysis of correlated traits via summary statistics from GWASs with an application in hypertension. Am J Hum Genet. 2015;96:21-36. PMCID:PMC4289691

[35] Wang K,Hakonarson H.ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.Nucleic Acids Res2010;38:e164 PMCID:PMC2938201

[36] Wallace C.Statistical testing of shared genetic control for potentially related traits.Genet Epidemiol2013;37:802-13 PMCID:PMC4158901

[37] Gusev A,Shi H.Integrative approaches for large-scale transcriptome-wide association studies.Nat Genet2016;48:245-52 PMCID:PMC4767558

[38] Zhu Z,Hu H.Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets.Nat Genet2016;48:481-7

[39] Bakshi A,Vinkhuyzen AA.Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits.Sci Rep2016;6:32894 PMCID:PMC5015118

[40] de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data.PLoS Comput Biol2015;11:e1004219 PMCID:PMC4401657

[41] Consortium. The GTEx consortium atlas of genetic regulatory effects across human tissues.Science2020;369:1318-30 PMCID:PMC7737656

[42] Feng H,Gusev A.Leveraging expression from multiple tissues using sparse canonical correlation analysis and aggregate tests improves the power of transcriptome-wide association studies.PLoS Genet2021;17:e1008973 PMCID:PMC8057593

[43] Xu S,Cai Y.Using clusterProfiler to characterize multiomics data.Nat Protoc2024;19:3292-320

[44] Dougherty JD,Nakajima M.Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells.Nucleic Acids Res2010;38:4218-30 PMCID:PMC2910036

[45] Dai Y,Liu A.WebCSEA: web-based cell-type-specific enrichment analysis of genes.Nucleic Acids Res2022;50:W782-90 PMCID:PMC10359109

[46] Xiong X,Ansari S.Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis.Mol Cell2019;75:644-60.e5 PMCID:PMC7262680

[47] Stuart T,Hoffman P.Comprehensive integration of single-cell data.Cell2019;177:1888-902.e21 PMCID:PMC6687398

[48] Korsunsky I,Fan J.Fast, sensitive and accurate integration of single-cell data with harmony.Nat Methods2019;16:1289-96 PMCID:PMC6884693

[49] Aran D,Liu L.Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage.Nat Immunol2019;20:163-72 PMCID:PMC6340744

[50] Saul D,Atkinson EJ.A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.Nat Commun2022;13:4827 PMCID:PMC9381717

[51] Cotto KC,Feng YY.DGIdb 3.0: a redesign and expansion of the drug-gene interaction database.Nucleic Acids Res2018;46:D1068-73 PMCID:PMC5888642

[52] Ursu O,Bologa CG.DrugCentral 2018: an update.Nucleic Acids Res2019;47:D963-70 PMCID:PMC6323925

[53] Barbarino JM,Altman RB.PharmGKB: a worldwide resource for pharmacogenomic information.Wiley Interdiscip Rev Syst Biol Med2018;10:e1417 PMCID:PMC6002921

[54] Mathews SE,Shukla AP.Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.Curr Opin Endocrinol Diabetes Obes2018;25:315-20

[55] Niederseer D,Aigner E,Datz C.NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations.J Clin Med2021;10:467 PMCID:PMC7865665

[56] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol2019;71:793-801

[57] Xie W,Zhou X.Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti.Cell Metab2024;36:1269-86.e9

[58] Zhao YC,Chen Z,Cai J.Nonalcoholic fatty liver disease: an emerging driver of hypertension.Hypertension2020;75:275-84

[59] Ren Z,Wesselius A,Brouwers MCGJ.Relationship between NAFLD and coronary artery disease: a Mendelian randomization study.Hepatology2023;77:230-8 PMCID:PMC9970021

[60] Park J,Kim H,Jin SM.The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study.Cardiovasc Diabetol2022;21:287 PMCID:PMC9789584

[61] Liu Y,Jin R.Associations of metabolic dysfunction-associated fatty liver disease with peripheral artery disease: prospective analysis in the UK biobank and ARIC study.J Am Heart Assoc2024;13:e035265 PMCID:PMC11681420

[62] Pandey N,Kaur H.Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis.J Thromb Haemost2024;22:3572-80 PMCID:PMC11608147

[63] Cho EJ,Yoo JJ.Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups.Cardiovasc Diabetol2024;23:340 PMCID:PMC11395983

[64] Jia Y,Yu J.Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm.Nutr Metab Cardiovasc Dis2024;34:953-62

[65] Bril F,Kalavalapalli S.Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes.J Clin Endocrinol Metab2021;106:e4360-71

[66] Pang Y,Turnbull I.Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people.Hepatology2018;68:1308-18 PMCID:PMC6220764

[67] Hu Y,Liu Y.Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease.Hypertens Res2024;47:1811-21

[68] Yuan M,Hu X.Hypertension and NAFLD risk: insights from the NHANES 2017-2018 and Mendelian randomization analyses.Chin Med J2024;137:457-64 PMCID:PMC10876227

[69] Ciardullo S,Sala I,Mancia G.Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories.Hypertension2020;76:562-8

[70] Song Q,Fan L.Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension.Chin Med J2023;136:1591-7 PMCID:PMC10325755

[71] Iwamoto S,Makishima S,Watanabe K.The role of TRIB1 in lipid metabolism; from genetics to pathways.Biochem Soc Trans2015;43:1063-8

[72] Functional analysis of the TRIB1 associated locus linked to plasma triglycerides and coronary artery disease.J Am Heart Assoc2016;5:e002056 PMCID:PMC4937239

[73] Kitamoto A,Nakamura T.Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.Endocr J2014;61:683-9

[74] Liu Q,Meng J.TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population.Lipids Health Dis2019;18:61 PMCID:PMC6408849

[75] Wang H.Lipoprotein lipase: from gene to obesity.Am J Physiol Endocrinol Metab2009;297:E271-88

[76] Goldberg IJ.2017 George Lyman Duff memorial lecture: fat in the blood, fat in the artery, fat in the heart: triglyceride in physiology and disease.Arterioscler Thromb Vasc Biol2018;38:700-6 PMCID:PMC5864527

[77] Chalasani N,Loomba R.PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Hepatology2024;80:1212-26 PMCID:PMC11798878

[78] Bruschi FV,Herac M,Trauner M.Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.Liver Int2020;40:1098-110 PMCID:PMC7318357

[79] Zhang G,He F.LDL-C and TC mediate the risk of PNPLA3 inhibition in cardiovascular diseases.J Clin Endocrinol Metab2025;110:e231-8

[80] Chen G,Zhang J.Additive genetic effect of GCKR, G6PC2, and SLC30A8 variants on fasting glucose levels and risk of type 2 diabetes.PLoS One2022;17:e0269378 PMCID:PMC9165855

[81] Vaxillaire M, Cavalcanti-Proença C, Dechaume A, et al; DESIR Study Group. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes. 2008;57:2253-7. PMCID:PMC2494697

[82] Socha P,Neuhoff-Murawska J,Podlesny J.Nonalcoholic fatty liver disease as a feature of the metabolic syndrome.Rocz Panstw Zakl Hig2007;58:129-37

[83] Petit JM,Guiu B.GCKR polymorphism influences liver fat content in patients with type 2 diabetes.Acta Diabetol2016;53:237-42

[84] Brouwers MCGJ,Stehouwer CDA.Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality.Diabetologia2020;63:253-60 PMCID:PMC6946734

[85] Ll, Siersbæk M, Mandrup S. PPARs: fatty acid sensors controlling metabolism.Semin Cell Dev Biol2012;23:631-9

[86] Qiu YY,Zeng FY.Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).Pharmacol Res2023;192:106786

[87] El Cheikh J, Hamed F, Rifi H, Dakroub AH, Eid AH. Genetic polymorphisms influencing antihypertensive drug responses.Br J Pharmacol2025;182:929-50

[88] Du Y,Wang L,Lip GYH.Extracellular vesicles in cardiovascular diseases: from pathophysiology to diagnosis and therapy.Cytokine Growth Factor Rev2023;74:40-55

[89] Li W,Chu Y.PLCE1 promotes myocardial ischemia-reperfusion injury in H/R H9c2 cells and I/R rats by promoting inflammation.Biosci Rep2019;39:BSR20181613 PMCID:PMC6609553

[90] Evangelou E, Warren HR, Mosen-Ansorena D, et al; Million Veteran Program. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412-25. PMCID:PMC6284793

[91] DeForest N,Zhu Z.Genome-wide discovery and integrative genomic characterization of insulin resistance loci using serum triglycerides to HDL-cholesterol ratio as a proxy.Nat Commun2024;15:8068 PMCID:PMC11401929

[92] Deprince A,Staels B.Dysregulated lipid metabolism links NAFLD to cardiovascular disease.Mol Metab2020;42:101092 PMCID:PMC7600388

[93] Castillo-Leon E,Konomi JV,Cleeton R.Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.Pediatr Obes2020;15:e12648

[94] Nass KJ,Faber KN,Blokzijl H.High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study.Metabolism2017;72:37-46

[95] Chandrasekharan K.Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy?.Front Pharmacol2020;10:1413 PMCID:PMC6960381

[96] Widjaja AA,Adami E.Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis.Gastroenterology2019;157:777-92.e14

[97] Vos DY.Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD).Mol Metab2021;50:101146 PMCID:PMC8324686

[98] Yu Y,An W,Zhang Y.STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis.J Clin Invest2019;129:546-55 PMCID:PMC6355218

[99] Jaitin DA,Thaiss CA.Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner.Cell2019;178:686-98.e14 PMCID:PMC7068689

[100] Cochain C,Arampatzi P.Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis.Circ Res2018;122:1661-74

[101] Magida JA.Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy.EMBO Mol Med2014;6:482-95 PMCID:PMC3992075

[102] Jamialahmadi O,Ciociola E.Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease.Gastroenterology2021;160:1634-46.e7

[103] van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF. Plasma ApoE elevations are associated with NAFLD: the PREVEND study.PLoS One2019;14:e0220659 PMCID:PMC6684074

[104] Byrne CD.Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.Diabetes Obes Metab2022;24:28-43

[105] Caussy C,Loomba R.The relationship between type 2 diabetes, NAFLD, and cardiovascular risk.Curr Diab Rep2021;21:15 PMCID:PMC8805985

[106] Armandi A,Caviglia GP.Insulin resistance across the spectrum of nonalcoholic fatty liver disease.Metabolites2021;11:155 PMCID:PMC8000048

[107] Matsusue K,Lambert G.Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.J Clin Invest2003;111:737-47 PMCID:PMC151902

[108] Brocker CN,Velenosi TJ.Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice.J Lipid Res2018;59:2140-52 PMCID:PMC6210912

[109] Sanderson LM,Desvergne B,Kersten S.Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver.Physiol Genomics2010;41:42-52

[110] Odegaard JI,Red Eagle A.Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance.Cell Metab2008;7:496-507 PMCID:PMC2587370

[111] Luo W,Wang Q,Hua J.Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease.Sci Rep2017;7:44612 PMCID:PMC5353732

[112] Fang J,Cao X.Transmissible endoplasmic reticulum stress mediated by extracellular vesicles from adipocyte promoting the senescence of adipose-derived mesenchymal stem cells in hypertrophic obesity.Oxid Med Cell Longev2022;2022:7175027 PMCID:PMC9410860

[113] Park SW,Lee J.The regulatory subunits of PI3K, p85α and p85β, interact with XBP-1 and increase its nuclear translocation.Nat Med2010;16:429-37 PMCID:PMC3071012

[114] Puri P,Cheung O.Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.Gastroenterology2008;134:568-76

[115] Fernandes-da-Silva A,Santana-Oliveira DA.Endoplasmic reticulum stress as the basis of obesity and metabolic diseases: focus on adipose tissue, liver, and pancreas.Eur J Nutr2021;60:2949-60

[116] Auer H,Rodríguez-Cruces R.From histology to macroscale function in the human amygdala.Elife2025;13:RP101950 PMCID:PMC11825128

[117] Gu Y,Hu Y,Shi J.Association between nonalcoholic fatty liver disease and depression: a systematic review and meta-analysis of observational studies.J Affect Disord2022;301:8-13

[118] Shea S,Kite C.Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.Front Endocrinol2024;15:1357664 PMCID:PMC11058984

[119] Qiao Y,Li G,Li S.Role of depression in the development of cardiometabolic multimorbidity: findings from the UK Biobank study.J Affect Disord2022;319:260-6

[120] Yang W,Wang S.Association of cardiometabolic multimorbidity with risk of late-life depression: a nationwide twin study.Eur Psychiatry2024;67:e58 PMCID:PMC11457118

[121] Celikbilek A,Bozkurt G.Cognitive assessment of patients with nonalcoholic fatty liver disease.Eur J Gastroenterol Hepatol2018;30:944-50

[122] Muzurović E,Belanger MJ,Mikhailidis DP.Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors.Hypertension2022;79:1319-26

[123] McCracken C,Veldsman M.Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants.Nat Commun2022;13:7839 PMCID:PMC9772225

[124] Binesh A,Halagowder D.Atherogenic diet induced lipid accumulation induced NFκB level in heart, liver and brain of Wistar rat and diosgenin as an anti-inflammatory agent.Life Sci2018;196:28-37

[125] Zheng J,Yang Q.Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study.EBioMedicine2023;96:104803 PMCID:PMC10514430

[126] Torres DM,Shaw JC,Ward JA.Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.Hepatology2011;54:1631-9

[127] Cusi K,Bril F.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.Ann Intern Med2016;165:305-15

[128] Ito D,Inoue K.Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial.Diabetes Care2017;40:1364-72

[129] Cosentino F,Ambery P.Cardiometabolic risk management: insights from a European society of cardiology cardiovascular round table.Eur Heart J2023;44:4141-56

[130] Wu S,Zhang Y.Sex and age differences in the association between metabolic dysfunction-associated fatty liver disease and heart failure: a prospective cohort study.Circ Heart Fail2024;17:e010841

[131] Yeh ML.From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: updates of nomenclature and impact on clinical trials.Clin Mol Hepatol2023;29:969-72 PMCID:PMC10577339